CO2023003009A2 - Anticuerpos multiespecíficos anti-tcr delta variable 1 - Google Patents

Anticuerpos multiespecíficos anti-tcr delta variable 1

Info

Publication number
CO2023003009A2
CO2023003009A2 CONC2023/0003009A CO2023003009A CO2023003009A2 CO 2023003009 A2 CO2023003009 A2 CO 2023003009A2 CO 2023003009 A CO2023003009 A CO 2023003009A CO 2023003009 A2 CO2023003009 A2 CO 2023003009A2
Authority
CO
Colombia
Prior art keywords
antibodies
bispecific
antigen
bind
cell
Prior art date
Application number
CONC2023/0003009A
Other languages
English (en)
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2023003009(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Publication of CO2023003009A2 publication Critical patent/CO2023003009A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos multiespecíficos, en particular biespecíficos, y fragmentos y variantes de estos que se unen específicamente al receptor de linfocitos T de linfocitos T gamma delta, y a otro antígeno. Más específicamente, la presente invención proporciona al menos dos nuevas clases de anticuerpos biespecíficos: acopladores de linfocitos T biespecíficos que se unen a la cadena variable delta 1 (Vδ1) de un receptor de linfocitos T γδ (TCR) y un antígeno del cáncer o un antígeno asociado al cáncer, e inmunomoduladores duales (DI) biespecíficos que se unen a la cadena variable delta 1 (Vδ1) de un receptor de linfocitos T γδ (TCR) y un antígeno inmunomodulador.
CONC2023/0003009A 2020-08-14 2023-03-13 Anticuerpos multiespecíficos anti-tcr delta variable 1 CO2023003009A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number Publication Date
CO2023003009A2 true CO2023003009A2 (es) 2023-03-17

Family

ID=80247426

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0003009A CO2023003009A2 (es) 2020-08-14 2023-03-13 Anticuerpos multiespecíficos anti-tcr delta variable 1

Country Status (18)

Country Link
EP (7) EP4218932A3 (es)
JP (1) JP2023537534A (es)
KR (1) KR20230083267A (es)
CN (1) CN116209456A (es)
AU (1) AU2021323512A1 (es)
BR (1) BR112023002741A2 (es)
CA (1) CA3188682A1 (es)
CO (1) CO2023003009A2 (es)
DK (1) DK4010082T3 (es)
ES (1) ES2943063T3 (es)
FI (1) FI4010082T3 (es)
IL (1) IL300517A (es)
LT (1) LT4010082T (es)
MX (1) MX2023001728A (es)
PL (1) PL4010082T3 (es)
PT (1) PT4010082T (es)
SI (1) SI4010082T1 (es)
WO (1) WO2022034562A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537534A (ja) 2020-08-14 2023-09-01 ガンマデルタ セラピューティクス リミテッド 多特異性抗ｔｃｒデルタ可変１抗体
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016198480A1 (en) 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
BR112018008293A2 (pt) 2015-10-30 2018-10-30 Cancer Research Tech Ltd expansão de células t gama delta não hematopoiéticas residentes no tecido e o uso dessas células
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
US11649286B2 (en) 2017-06-25 2023-05-16 Systimmune Inc. Tri-specific antibodies
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
US20220111043A1 (en) * 2018-09-19 2022-04-14 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US20220135694A1 (en) * 2019-02-01 2022-05-05 Lava Therapeutics B.V. Novel cd40-binding antibodies
KR20220006065A (ko) 2019-04-08 2022-01-14 메모리얼 슬로안 케터링 캔서 센터 Cd19 항체 및 이의 사용 방법
CA3145517A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Novel anti-tcr delta variable 1 antibodies
EP4013787A1 (en) 2019-08-16 2022-06-22 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
JP2023537534A (ja) 2020-08-14 2023-09-01 ガンマデルタ セラピューティクス リミテッド 多特異性抗ｔｃｒデルタ可変１抗体
US20230028110A1 (en) 2021-02-17 2023-01-26 Adaptate Biotherapeutics Ltd. Anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
EP4269444A3 (en) 2024-02-14
KR20230083267A (ko) 2023-06-09
EP4265643A3 (en) 2024-02-14
JP2023537534A (ja) 2023-09-01
SI4010082T1 (sl) 2023-04-28
EP4010082A1 (en) 2022-06-15
PT4010082T (pt) 2023-04-26
EP4269445A3 (en) 2024-02-14
CA3188682A1 (en) 2022-02-17
MX2023001728A (es) 2023-04-20
EP4269445A2 (en) 2023-11-01
ES2943063T3 (es) 2023-06-08
FI4010082T3 (fi) 2023-04-04
EP4265643A2 (en) 2023-10-25
EP4265642A2 (en) 2023-10-25
EP4218932A2 (en) 2023-08-02
WO2022034562A1 (en) 2022-02-17
IL300517A (en) 2023-04-01
EP4269446A3 (en) 2024-02-14
EP4269446A2 (en) 2023-11-01
DK4010082T3 (da) 2023-04-03
LT4010082T (lt) 2023-03-10
EP4269444A2 (en) 2023-11-01
EP4218932A3 (en) 2023-09-27
EP4010082B1 (en) 2023-01-25
EP4265642A3 (en) 2024-02-14
PL4010082T3 (pl) 2023-05-29
AU2021323512A1 (en) 2023-04-13
BR112023002741A2 (pt) 2023-10-10
CN116209456A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
CO2023003009A2 (es) Anticuerpos multiespecíficos anti-tcr delta variable 1
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112018067458A2 (pt) anticorpos para tigit
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
BR112017025332A2 (pt) anticorpos específicos de receptor de célula t
EA201990183A1 (ru) Аденовирус, вооруженный биспецифичным активатором т-клеток (bite)
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
DOP2022000275A (es) Captadores de células inmunitarias biespecíficas con especificidad de unión para hla-g y otro antígeno
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CO2023002034A2 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
BR112021026309A2 (pt) Anticorpos para ativação de células t
CO2022001021A2 (es) Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
MX2022005238A (es) Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1